CHAPEL HILL, N.C. — iOrganBio, a company specializing in intelligent cell manufacturing, has appointed Zhiping Pang, M.D., Ph.D., to its Scientific Advisory Board. Dr. Pang is a leading expert in human neuron biology, synaptic function, and the molecular mechanisms underlying neuropsychiatric and metabolic disorders. He brings more than 140 publications in top journals including Nature, Science, Nature Neuroscience, and Nature Metabolism.
Dr. Pang serves as the Henry Rutgers Professor of NeuroMetabolism and Professor of Neuroscience and Cell Biology at Rutgers Robert Wood Johnson Medical School, and Director of the Center for NeuroMetabolism at Rutgers Health. His appointment bolsters iOrganBio's scientific breadth as the field moves toward more human-relevant, non-animal systems for research and drug development.
iOrganBio's CellForge platform uses artificial intelligence and automation to guide cell development, making real-time adjustments aligned with defined biological profiles. The platform relies on the company's functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type. This closed-loop process aims to deliver accuracy, efficiency, and quality for partners in disease modeling, regenerative medicine, and drug development.
For business leaders and researchers, this appointment signals iOrganBio's commitment to advancing FDA-aligned New Approach Methodologies (NAMs) that reduce reliance on animal testing. By adding a neuroscientist of Dr. Pang's caliber, the company strengthens its ability to produce consistent, scalable human cells and organoids for studying neurological disorders such as Alzheimer's, Parkinson's, and metabolic conditions.
The implications for the pharmaceutical industry are significant. Reliable production of human neurons and organoids could accelerate drug discovery and reduce costs associated with late-stage failures. The U.S. Food and Drug Administration (FDA) has been encouraging the use of NAMs, and iOrganBio's platform aligns with this regulatory direction.
For investors, the addition of a prominent academic figure to the advisory board enhances the company's credibility and potential for partnerships. As the field of AI-enabled biology grows, iOrganBio positions itself at the intersection of automation and cell engineering, a market with substantial growth potential.
More information about iOrganBio and its technology can be found on its website at iOrgan.Bio.
